Komatsu Hiroyuki, Fujimoto Shouichi, Hara Seiichiro, Sato Yuji, Yamada Kazuhiro, Kitamura Kazuo
Circulatory and Body Fluid Regulation, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Kiyotake, Miyazaki, 889-1692, Japan.
Clin J Am Soc Nephrol. 2008 Sep;3(5):1301-7. doi: 10.2215/CJN.00310108. Epub 2008 May 28.
Few well-designed investigations have examined how tonsillectomy plus steroid pulse therapy affects IgA nephropathy. A prospective, controlled study therefore was performed to compare the effects of combined therapy with those of steroid pulse alone in patients with IgA nephropathy.
DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Fifty-five patients were followed up for 54.0 +/- 21.2 mo. Thirty-five of them underwent tonsillectomy and steroid pulse therapy (group C), and 20 received steroid pulse monotherapy (group M). Both groups received methylprednisolone intravenously, followed by oral prednisolone (initial dosage 0.5 mg/kg per d) for 12 to 18 mo. Primary evaluation items were a 100% increase in serum creatinine from baseline levels or the disappearance of urinary protein (UP) and/or occult blood (UOB) indicating clinical remission.
At 24 mo after the initial treatment, the ratios of the UP and UOB disappearance were higher in group C than in group M, and the therapeutic effect persisted until the final observation. None of group C achieved a 100% increase in serum creatinine from the baseline level, whereas one patient in group M developed ESRD during the observation period. The histologic findings of repeated biopsy specimens from 18 patients revealed that mesangial proliferation and IgA deposition were significantly more reduced in group C than in group M. The Cox regression model showed that the combined therapy was approximately six-fold more effective in causing the disappearance of UP than steroid pulse monotherapy.
Tonsillectomy combined with steroid pulse treatment can induce clinical remission in patients with IgA nephropathy.
很少有设计良好的研究探讨扁桃体切除术加类固醇冲击疗法对IgA肾病的影响。因此,我们进行了一项前瞻性对照研究,比较联合治疗与单独使用类固醇冲击疗法对IgA肾病患者的疗效。
设计、地点、参与者及测量指标:55例患者接受了54.0±21.2个月的随访。其中35例接受了扁桃体切除术和类固醇冲击疗法(C组),20例接受了类固醇冲击单一疗法(M组)。两组均静脉注射甲泼尼龙,随后口服泼尼松龙(初始剂量为每日0.5mg/kg),持续12至18个月。主要评估指标为血清肌酐较基线水平升高100%或尿蛋白(UP)和/或潜血(UOB)消失,提示临床缓解。
初始治疗后24个月时,C组UP和UOB消失的比例高于M组,且治疗效果持续至最终观察期。C组中无患者血清肌酐较基线水平升高100%,而M组有1例患者在观察期内发展为终末期肾病(ESRD)。对18例患者重复活检标本的组织学检查发现,C组系膜增生和IgA沉积的减少程度明显大于M组。Cox回归模型显示,联合治疗导致UP消失的效果比类固醇冲击单一疗法高约6倍。
扁桃体切除术联合类固醇冲击治疗可使IgA肾病患者实现临床缓解。